We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Read MoreHide Full Article
Key Takeaways
SRPT stock rose nearly 2% as enrollment began in cohort 8 of the phase Ib ENDEAVOR study.
Sarepta tests sirolimus regimen to reduce Elevidys-related liver risks in non-ambulatory DMD patients.
SRPT targets 25 patients, studying dose timings to address safety concerns after prior liver-related deaths.
Shares of Sarepta Therapeutics (SRPT - Free Report) rose about 2% yesterday after it announced that screening and enrollment are underway in cohort 8 of the phase Ib ENDEAVOR study.
This cohort is designed to improve the safety profile of Elevidys — its one-shot gene therapy for Duchenne muscular dystrophy (DMD) — in non-ambulatory patients by combining it with an enhanced sirolimus-based immunosuppressive regimen.
Data from this cohort will be used to determine whether administering sirolimus before or after Elevidys infusion can help reduce the risk of acute liver complications. Sarepta plans to enroll around 25 non-ambulatory patients with DMD in the United States who will receive the immunosuppressive regimen. This will include 14 days of sirolimus dosing before Elevidys infusion, followed by 12 weeks of treatment after infusion.
The company developed Elevidys in partnership with pharma giant Roche (RHHBY - Free Report) . In 2019, Sarepta and Roche entered into a licensing agreement to develop Elevidys. Per the agreement, Roche has exclusive rights to launch and market the therapy in non-U.S. markets.
SRPT’s Stock Performance
In the past year, the stock has plunged nearly 84% against the industry’s 11% growth.
Image Source: Zacks Investment Research
More on Sarepta’s Elevidys
Sarepta has been facing a lot of heat from investors after three patient deaths were linked to its gene therapy treatments and attributed to acute liver failure (ALF). While two deaths occurred in patients after receiving Elevidys, one was caused by an experimental limb-girdle muscular dystrophy (LGMD) therapy. All deaths occurred in non-ambulatory patients and were linked to the AAVrh74 gene therapy vector used in both Elevidys and Sarepta’s experimental LGMD therapies.
Based on these events, the FDA approved significant changes to the label of Elevidys last November. Under the revised label, the gene therapy is now approved only for ambulatory patients aged four years and older with DMD. It is no longer authorized for use in non-ambulatory patients. Elevidys is mandated to carry a boxed warning — the most important safety warning issued by the FDA — highlighting the risks of ALF and acute liver injury (ALI).
The agency added additional limitations to the gene therapy’s label. It is no longer recommended for patients with pre-existing liver impairment, recent vaccinations or active/recent infections. The updated label introduces new monitoring requirements, including weekly liver function tests for at least three months post-treatment. Patients are advised to remain near an appropriate medical facility for at least two months after infusion to ensure rapid access to care if complications arise.
Following these setbacks, Sarepta paused development of most of its LGMD pipeline and shifted focus to the siRNA programs, which were acquired last year as part of a multi-billion-dollar licensing deal with Arrowhead Pharmaceuticals .
View the Zacks #1 Rank List
Image: Bigstock
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Key Takeaways
Shares of Sarepta Therapeutics (SRPT - Free Report) rose about 2% yesterday after it announced that screening and enrollment are underway in cohort 8 of the phase Ib ENDEAVOR study.
This cohort is designed to improve the safety profile of Elevidys — its one-shot gene therapy for Duchenne muscular dystrophy (DMD) — in non-ambulatory patients by combining it with an enhanced sirolimus-based immunosuppressive regimen.
Data from this cohort will be used to determine whether administering sirolimus before or after Elevidys infusion can help reduce the risk of acute liver complications. Sarepta plans to enroll around 25 non-ambulatory patients with DMD in the United States who will receive the immunosuppressive regimen. This will include 14 days of sirolimus dosing before Elevidys infusion, followed by 12 weeks of treatment after infusion.
The company developed Elevidys in partnership with pharma giant Roche (RHHBY - Free Report) . In 2019, Sarepta and Roche entered into a licensing agreement to develop Elevidys. Per the agreement, Roche has exclusive rights to launch and market the therapy in non-U.S. markets.
SRPT’s Stock Performance
In the past year, the stock has plunged nearly 84% against the industry’s 11% growth.
Image Source: Zacks Investment Research
More on Sarepta’s Elevidys
Sarepta has been facing a lot of heat from investors after three patient deaths were linked to its gene therapy treatments and attributed to acute liver failure (ALF). While two deaths occurred in patients after receiving Elevidys, one was caused by an experimental limb-girdle muscular dystrophy (LGMD) therapy. All deaths occurred in non-ambulatory patients and were linked to the AAVrh74 gene therapy vector used in both Elevidys and Sarepta’s experimental LGMD therapies.
Based on these events, the FDA approved significant changes to the label of Elevidys last November. Under the revised label, the gene therapy is now approved only for ambulatory patients aged four years and older with DMD. It is no longer authorized for use in non-ambulatory patients. Elevidys is mandated to carry a boxed warning — the most important safety warning issued by the FDA — highlighting the risks of ALF and acute liver injury (ALI).
The agency added additional limitations to the gene therapy’s label. It is no longer recommended for patients with pre-existing liver impairment, recent vaccinations or active/recent infections. The updated label introduces new monitoring requirements, including weekly liver function tests for at least three months post-treatment. Patients are advised to remain near an appropriate medical facility for at least two months after infusion to ensure rapid access to care if complications arise.
Following these setbacks, Sarepta paused development of most of its LGMD pipeline and shifted focus to the siRNA programs, which were acquired last year as part of a multi-billion-dollar licensing deal with Arrowhead Pharmaceuticals .
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote
SRPT’s Zacks Rank
Sarepta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.